Q3 2025 · 13F-HR
Krensavage Asset Management, LLCholdings as filed
Filed 2025-11-17 · accession 0001609251-25-000007
$234,698
Reported value
17
Positions
2025-09-30
Period end
The Brief · Krensavage Asset Management, LLC · Q3 2025
AI · grounded in 13F
Krensavage Asset Management, LLC established a new position in UTHR valued at $40,934. The fund also initiated new stakes in ENTA for $25,310 and JAZZ for $22,118. Other new additions include BMRN, EXEL, and SUPN. The fund ended the period with 17 positions and total AUM of $234,698.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $40,934 | 17.4% | 97,646 | Common | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $25,310 | 10.8% | 2,114,444 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $22,118 | 9.42% | 167,816 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $21,959 | 9.36% | 405,450 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $21,415 | 9.12% | 518,526 | Common | SOLE |
| 868459108 | SUPN | SUPERNUS PHARMACEUTICALS INC | $17,371 | 7.40% | 363,479 | Common | SOLE |
| 80105N105 | SNY | SANOFI-ADR | $15,290 | 6.51% | 323,946 | Common | SOLE |
| G29687103 | AVDL | AVADEL PHARMACEUTICALS | $14,596 | 6.22% | 955,860 | Common | SOLE |
| 37733W204 | GSK | GSK PLC-SPON ADR | $11,728 | 5.00% | 271,729 | Common | SOLE |
| 14149Y108 | CAH | CARDINAL HEALTH INC | $11,575 | 4.93% | 73,745 | Common | SOLE |
| G4766E116 | INDV | INDIVIOR PLC | $8,186 | 3.49% | 339,532 | Common | SOLE |
| 09075V102 | BNTX | BIONTECH SE-ADR | $7,827 | 3.33% | 79,366 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $6,235 | 2.66% | 207,822 | Common | SOLE |
| 921659108 | VNDA | VANDA PHARMACEUTICALS INC | $5,890 | 2.51% | 1,180,388 | Common | SOLE |
| 75886F107 | REGN | REGENERON PHARMACEUTICALS | $2,249 | 0.96% | 4,000 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $1,401 | 0.60% | 10,000 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $614 | 0.26% | 100,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.